FDA's approved drug for Parkinson is under new review
Mar 29, 2019
After approving a groundbreaking medication for patients with Parkinson, organizations are looking over the risks again due to the new data of deaths regarding the medication. Nuplazid helps fight the hallucinations and delusions from the disease. The secondary effects of the drug are the same as when it was first presented. Experts from the FDA decided to approve the drug due to the high demand it had among patients with Parkinson. The drug company and the FDA have stated that these deaths have happened due to the already declining health from the patients. The FDA declined to give a response to the reports made by the ISMP (Institute from Safe Medication Practices), one of the organizations supervising the review.